Anika Wuestefeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anika Wuestefeld has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Laura E. M. Wisse
Department of Diagnostic Radiology, Lund University, Lund, Sweden
7 shared publications - David Berron
German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
6 shared publications Olof Strandberg
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
6 shared publications- Hannah Baumeister
German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
5 shared publications Danielle van Westen
Department of Clinical Sciences Lund Lund University, Lunds Universitet/SUS/Lund Lund Sweden
4 shared publicationsDavid Berron
German Center for Neurodegenerative Diseases (DZNE) Magdeburg Germany
4 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71462
Speech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts
INTRODUCTION: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease‐modifying treatments emerge. Speech‐based digital biomarkers offer scalable options for remotely capturing speech‐derived functional changes associated with early cognitive decline, but validation across real‐world populations remains limited. METHODS: We evaluated the speech biomarker for cognition (SB‐C), an automated speech‐derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at‐risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER‐Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app‐based platforms. SB‐C performance was compared to Mini‐Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status. RESULTS: SB‐C significantly differentiated cognitively unimpaired and impaired groups ( P < 0.001), correlated with standard cognitive measures, and showed moderate‐to‐high area under the curve (0.56–0.82) for classifying biomarker positivity, with strongest results in BioFINDER‐Primary Care. DISCUSSION: SB‐C is a scalable, remote speech‐derived marker associated with cognitive status and AD biomarker group differences.
- 18 May 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (5) , e71462
Open AccessSpeech‐based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts
INTRODUCTION: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease‐modifying treatments emerge. Speech‐based digital biomarkers offer scalable options for remotely capturing speech‐derived functional changes associated with early cognitive decline, but validation across real‐world populations remains limited. METHODS: We evaluated the speech biomarker for cognition (SB‐C), an automated speech‐derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at‐risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER‐Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app‐based platforms. SB‐C performance was compared to Mini‐Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status. RESULTS: SB‐C significantly differentiated cognitively unimpaired and impaired groups ( P < 0.001), correlated with standard cognitive measures, and showed moderate‐to‐high area under the curve (0.56–0.82) for classifying biomarker positivity, with strongest results in BioFINDER‐Primary Care. DISCUSSION: SB‐C is a scalable, remote speech‐derived marker associated with cognitive status and AD biomarker group differences.
- Open Access
- 25 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70511
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION: A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration on tau‐induced domain‐specific cognitive impairment in amyloid‐beta (Aβ) positive cognitively normal and impaired adults. METHODS: We assessed magnetic resonance imaging–derived MTL and neocortical volume/thickness and 18 F‐Flortaucipir positron emission tomography in 319 Aβ‐positive individuals. Cognitive functions across six domains were isolated by adjusting for other cognitive measures. RESULTS: MTL tau correlated with memory subdomains, neocortical tau with executive function, and both with semantic fluency. Specific structural measures partially mediated these tau–cognition associations: Brodmann area 35 mediated tau–immediate and tau–delayed recall, posterior hippocampus tau–recognition, and inferior temporal cortex tau–semantic fluency associations. DISCUSSION: Our findings provide a nuanced understanding of region‐specific macrostructural atrophy as one pathway of tau‐induced cognitive changes, aligning with known tau spread patterns. Additionally, isolating cognitive functions is a promising approach for future research. Highlights: Medial temporal lobe tau was related to memory domains; neocortical tau to executive function. Both tau positron emission tomography measures were associated with semantic fluency. Specific regional atrophy partially mediated tau‐induced cognitive changes. Other mechanistic links between tau and cognitive subdomains require investigation. Isolated cognitive domains should be explored as future avenues of research.
- 25 July 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (7) , e70511
Open AccessTau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION: A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's disease is crucial. We investigate mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration on tau‐induced domain‐specific cognitive impairment in amyloid‐beta (Aβ) positive cognitively normal and impaired adults. METHODS: We assessed magnetic resonance imaging–derived MTL and neocortical volume/thickness and 18 F‐Flortaucipir positron emission tomography in 319 Aβ‐positive individuals. Cognitive functions across six domains were isolated by adjusting for other cognitive measures. RESULTS: MTL tau correlated with memory subdomains, neocortical tau with executive function, and both with semantic fluency. Specific structural measures partially mediated these tau–cognition associations: Brodmann area 35 mediated tau–immediate and tau–delayed recall, posterior hippocampus tau–recognition, and inferior temporal cortex tau–semantic fluency associations. DISCUSSION: Our findings provide a nuanced understanding of region‐specific macrostructural atrophy as one pathway of tau‐induced cognitive changes, aligning with known tau spread patterns. Additionally, isolating cognitive functions is a promising approach for future research. Highlights: Medial temporal lobe tau was related to memory domains; neocortical tau to executive function. Both tau positron emission tomography measures were associated with semantic fluency. Specific regional atrophy partially mediated tau‐induced cognitive changes. Other mechanistic links between tau and cognitive subdomains require investigation. Isolated cognitive domains should be explored as future avenues of research.
- Open Access
Disease stage-specific atrophy markers in Alzheimer’s disease
INTRODUCTION: Structural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer’s disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases. METHODS: We included 363 older adults; healthy controls (HC) who were negative or positive for amyloid-beta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years. RESULTS: Accelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage. DISCUSSION: With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
Open AccessDisease stage-specific atrophy markers in Alzheimer’s disease
INTRODUCTION: Structural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer’s disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases. METHODS: We included 363 older adults; healthy controls (HC) who were negative or positive for amyloid-beta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years. RESULTS: Accelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage. DISCUSSION: With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S9)
The association between tau pathology and later stages of memory processing is mediated by medial temporal lobe atrophy in typical Alzheimer's Disease
Background: Tau pathology is closely related to cognitive decline in Alzheimer’s disease (AD). Neurodegeneration is the putative mechanism by which tau leads to cognitive deficits. However, there is limited work on the associations between tau, neurodegeneration, and specific cognitive domains. We investigate potential mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration for different cognitive domains in amyloid‐ß‐positive (Aß+) adults.Method: We included 325 positron emission tomography (PET) Aß+ individuals across the AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (age: 72±8 [55–90]; 51.1% female, education: 16±2 years). Hippocampal volume and cortical thickness were measured from T1‐weighted structural magnetic resonance imaging in typical AD regions (Fig. 1). Using flortaucipir‐PET, tau was quantified for two composite regions (MTL, neocortical). Included cognitive measures are shown in Fig. 1. Mediation analyses between tau‐PET, thickness/volume, and cognition were performed. Cognitive measures were adjusted to isolate the function of interest (Fig. 1).Result: Higher tau‐PET uptake and lower thickness were associated with lower performance on all cognitive measures. In simple mediations, tau‐immediate recall associations were mediated by MTL, parietal, and temporal regions (Fig. 2A). Tau‐delayed recall associations were mediated by MTL regions. Tau‐late recall and tau‐recognition associations were mediated by MTL and parietal regions. Tau‐fluency and tau‐executive functioning associations were mediated by MTL and parietal regions, as well as temporal regions for fluency. Complex mediations investigated significant mediators simultaneously (Fig. 2B+3). Depending if MTL/neocortical tau remained significant when covarying for the other tau measure in a regression, the complex mediation models focused on MTL and/or neocortical regions (Fig. 2B description). Hippocampus mediated the tau‐late recall and tau‐recognition associations. Brodmann area 35 mediated the tau‐delayed recall association. Tau‐fluency was, at a trend level, mediated by inferior temporal thickness. Tau‐executive functioning did not demonstrate a mediation effect, potentially due to limited frontal atrophy. All mediators were partial mediators explaining up to 23% of variance.Conclusion: The results suggest that MTL tau pathology, partially mediated by macrostructural changes, lead to impairments in specific memory domains in early AD. Impairments in fluency and executive functioning, however, seem more likely to follow from tau‐induced effects in neocortical regions.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S9)
Open AccessThe association between tau pathology and later stages of memory processing is mediated by medial temporal lobe atrophy in typical Alzheimer's Disease
Background: Tau pathology is closely related to cognitive decline in Alzheimer’s disease (AD). Neurodegeneration is the putative mechanism by which tau leads to cognitive deficits. However, there is limited work on the associations between tau, neurodegeneration, and specific cognitive domains. We investigate potential mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration for different cognitive domains in amyloid‐ß‐positive (Aß+) adults.Method: We included 325 positron emission tomography (PET) Aß+ individuals across the AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (age: 72±8 [55–90]; 51.1% female, education: 16±2 years). Hippocampal volume and cortical thickness were measured from T1‐weighted structural magnetic resonance imaging in typical AD regions (Fig. 1). Using flortaucipir‐PET, tau was quantified for two composite regions (MTL, neocortical). Included cognitive measures are shown in Fig. 1. Mediation analyses between tau‐PET, thickness/volume, and cognition were performed. Cognitive measures were adjusted to isolate the function of interest (Fig. 1).Result: Higher tau‐PET uptake and lower thickness were associated with lower performance on all cognitive measures. In simple mediations, tau‐immediate recall associations were mediated by MTL, parietal, and temporal regions (Fig. 2A). Tau‐delayed recall associations were mediated by MTL regions. Tau‐late recall and tau‐recognition associations were mediated by MTL and parietal regions. Tau‐fluency and tau‐executive functioning associations were mediated by MTL and parietal regions, as well as temporal regions for fluency. Complex mediations investigated significant mediators simultaneously (Fig. 2B+3). Depending if MTL/neocortical tau remained significant when covarying for the other tau measure in a regression, the complex mediation models focused on MTL and/or neocortical regions (Fig. 2B description). Hippocampus mediated the tau‐late recall and tau‐recognition associations. Brodmann area 35 mediated the tau‐delayed recall association. Tau‐fluency was, at a trend level, mediated by inferior temporal thickness. Tau‐executive functioning did not demonstrate a mediation effect, potentially due to limited frontal atrophy. All mediators were partial mediators explaining up to 23% of variance.Conclusion: The results suggest that MTL tau pathology, partially mediated by macrostructural changes, lead to impairments in specific memory domains in early AD. Impairments in fluency and executive functioning, however, seem more likely to follow from tau‐induced effects in neocortical regions.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S3) , e087337
The association between tau pathology and later stages of memory processing is mediated by medial temporal lobe atrophy in typical Alzheimer’s Disease
Background: Tau pathology is closely related to cognitive decline in Alzheimer’s disease (AD). Neurodegeneration is the putative mechanism by which tau leads to cognitive deficits. However, there is limited work on the associations between tau, neurodegeneration, and specific cognitive domains. We investigate potential mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration for different cognitive domains in amyloid‐β‐positive (Aβ+) adults.Method: We included 325 positron emission tomography (PET) Aβ+ individuals across the AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (age: 72±8 [55–90]; 51.1% female, education: 16±2 years). Hippocampal volume and cortical thickness were measured from T1‐weighted structural magnetic resonance imaging in typical AD regions (Fig. 1). Using flortaucipir‐PET, tau was quantified for two composite regions (MTL, neocortical). Included cognitive measures are shown in Fig. 1. Mediation analyses between tau‐PET, thickness/volume, and cognition were performed. Cognitive measures were adjusted to isolate the function of interest (Fig. 1).Result: Higher tau‐PET uptake and lower thickness were associated with lower performance on all cognitive measures.In simple mediations, tau‐immediate recall associations were mediated by MTL, parietal, and temporal regions (Fig. 2A). Tau‐delayed recall associations were mediated by MTL regions. Tau‐late recall and tau‐recognition associations were mediated by MTL and parietal regions. Tau‐fluency and tau‐executive functioning associations were mediated by MTL and parietal regions, as well as temporal regions for fluency.Complex mediations investigated significant mediators simultaneously (Fig. 2B+3). Depending if MTL/neocortical tau remained significant when covarying for the other tau measure in a regression, the complex mediation models focused on MTL and/or neocortical regions (Fig. 2B description). Hippocampus mediated the tau‐late recall and tau‐recognition associations. Brodmann area 35 mediated the tau‐delayed recall association. Tau‐fluency was, at a trend level, mediated by inferior temporal thickness. Tau‐executive functioning did not demonstrate a mediation effect, potentially due to limited frontal atrophy. All mediators were partial mediators explaining up to 23% of variance.Conclusion: The results suggest that MTL tau pathology, partially mediated by macrostructural changes, lead to impairments in specific memory domains in early AD. Impairments in fluency and executive functioning, however, seem more likely to follow from tau‐induced effects in neocortical regions.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S3) , e087337
Open AccessThe association between tau pathology and later stages of memory processing is mediated by medial temporal lobe atrophy in typical Alzheimer’s Disease
Background: Tau pathology is closely related to cognitive decline in Alzheimer’s disease (AD). Neurodegeneration is the putative mechanism by which tau leads to cognitive deficits. However, there is limited work on the associations between tau, neurodegeneration, and specific cognitive domains. We investigate potential mediating effects of medial temporal lobe (MTL) and neocortical neurodegeneration for different cognitive domains in amyloid‐β‐positive (Aβ+) adults.Method: We included 325 positron emission tomography (PET) Aβ+ individuals across the AD spectrum from the Alzheimer’s Disease Neuroimaging Initiative (age: 72±8 [55–90]; 51.1% female, education: 16±2 years). Hippocampal volume and cortical thickness were measured from T1‐weighted structural magnetic resonance imaging in typical AD regions (Fig. 1). Using flortaucipir‐PET, tau was quantified for two composite regions (MTL, neocortical). Included cognitive measures are shown in Fig. 1. Mediation analyses between tau‐PET, thickness/volume, and cognition were performed. Cognitive measures were adjusted to isolate the function of interest (Fig. 1).Result: Higher tau‐PET uptake and lower thickness were associated with lower performance on all cognitive measures.In simple mediations, tau‐immediate recall associations were mediated by MTL, parietal, and temporal regions (Fig. 2A). Tau‐delayed recall associations were mediated by MTL regions. Tau‐late recall and tau‐recognition associations were mediated by MTL and parietal regions. Tau‐fluency and tau‐executive functioning associations were mediated by MTL and parietal regions, as well as temporal regions for fluency.Complex mediations investigated significant mediators simultaneously (Fig. 2B+3). Depending if MTL/neocortical tau remained significant when covarying for the other tau measure in a regression, the complex mediation models focused on MTL and/or neocortical regions (Fig. 2B description). Hippocampus mediated the tau‐late recall and tau‐recognition associations. Brodmann area 35 mediated the tau‐delayed recall association. Tau‐fluency was, at a trend level, mediated by inferior temporal thickness. Tau‐executive functioning did not demonstrate a mediation effect, potentially due to limited frontal atrophy. All mediators were partial mediators explaining up to 23% of variance.Conclusion: The results suggest that MTL tau pathology, partially mediated by macrostructural changes, lead to impairments in specific memory domains in early AD. Impairments in fluency and executive functioning, however, seem more likely to follow from tau‐induced effects in neocortical regions.
- Open Access
- 15 October 2024
- Published by Wiley in Human Brain Mapping
- Vol. 45 (15) , e70004
A (sub)field guide to quality control in hippocampal subfield segmentation on high‐resolution T2‐weighted MRI
Inquiries into properties of brain structure and function have progressed due to developments in magnetic resonance imaging (MRI). To sustain progress in investigating and quantifying neuroanatomical details in vivo, the reliability and validity of brain measurements are paramount. Quality control (QC) is a set of procedures for mitigating errors and ensuring the validity and reliability of brain measurements. Despite its importance, there is little guidance on best QC practices and reporting procedures. The study of hippocampal subfields in vivo is a critical case for QC because of their small size, inter‐dependent boundary definitions, and common artifacts in the MRI data used for subfield measurements. We addressed this gap by surveying the broader scientific community studying hippocampal subfields on their views and approaches to QC. We received responses from 37 investigators spanning 10 countries, covering different career stages, and studying both healthy and pathological development and aging. In this sample, 81% of researchers considered QC to be very important or important, and 19% viewed it as fairly important. Despite this, only 46% of researchers reported on their QC processes in prior publications. In many instances, lack of reporting appeared due to ambiguous guidance on relevant details and guidance for reporting, rather than absence of QC. Here, we provide recommendations for correcting errors to maximize reliability and minimize bias. We also summarize threats to segmentation accuracy, review common QC methods, and make recommendations for best practices and reporting in publications. Implementing the recommended QC practices will collectively improve inferences to the larger population, as well as have implications for clinical practice and public health.
- 15 October 2024
- Published by Wiley in Human Brain Mapping
- Vol. 45 (15) , e70004
Open AccessA (sub)field guide to quality control in hippocampal subfield segmentation on high‐resolution T2‐weighted MRI
Inquiries into properties of brain structure and function have progressed due to developments in magnetic resonance imaging (MRI). To sustain progress in investigating and quantifying neuroanatomical details in vivo, the reliability and validity of brain measurements are paramount. Quality control (QC) is a set of procedures for mitigating errors and ensuring the validity and reliability of brain measurements. Despite its importance, there is little guidance on best QC practices and reporting procedures. The study of hippocampal subfields in vivo is a critical case for QC because of their small size, inter‐dependent boundary definitions, and common artifacts in the MRI data used for subfield measurements. We addressed this gap by surveying the broader scientific community studying hippocampal subfields on their views and approaches to QC. We received responses from 37 investigators spanning 10 countries, covering different career stages, and studying both healthy and pathological development and aging. In this sample, 81% of researchers considered QC to be very important or important, and 19% viewed it as fairly important. Despite this, only 46% of researchers reported on their QC processes in prior publications. In many instances, lack of reporting appeared due to ambiguous guidance on relevant details and guidance for reporting, rather than absence of QC. Here, we provide recommendations for correcting errors to maximize reliability and minimize bias. We also summarize threats to segmentation accuracy, review common QC methods, and make recommendations for best practices and reporting in publications. Implementing the recommended QC practices will collectively improve inferences to the larger population, as well as have implications for clinical practice and public health.
- Open Access
- 16 September 2024
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1-12
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease
Background: The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfields and drivers of atrophy in amnestic EOAD is lacking. Methods: BioFINDER-2 participants with memory impairment, abnormal amyloid-β and tau-PET were included. Forty-one amnestic EOAD individuals ≤65 years and, as comparison, late-onset AD (aLOAD, ≥70 years, n = 154) and amyloid-β-negative cognitively unimpaired controls were included. MTL subregions and biomarkers of (co-)pathologies were measured. Results: AD groups showed smaller MTL subregions compared to controls. Atrophy patterns were similar across AD groups: aLOAD showed thinner entorhinal cortices than aEOAD; aEOAD showed thinner parietal regions than aLOAD. aEOAD showed lower white matter hyperintensities than aLOAD. No differences in MTL tau-PET or transactive response DNA binding protein 43-proxy positivity were found. Conclusions: We found evidence for MTL atrophy in amnestic EOAD and overall similar levels to aLOAD of MTL tau pathology and co-pathologies.
- 16 September 2024
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 16 (1) , 1-12
Open AccessMedial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease
Background: The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfields and drivers of atrophy in amnestic EOAD is lacking. Methods: BioFINDER-2 participants with memory impairment, abnormal amyloid-β and tau-PET were included. Forty-one amnestic EOAD individuals ≤65 years and, as comparison, late-onset AD (aLOAD, ≥70 years, n = 154) and amyloid-β-negative cognitively unimpaired controls were included. MTL subregions and biomarkers of (co-)pathologies were measured. Results: AD groups showed smaller MTL subregions compared to controls. Atrophy patterns were similar across AD groups: aLOAD showed thinner entorhinal cortices than aEOAD; aEOAD showed thinner parietal regions than aLOAD. aEOAD showed lower white matter hyperintensities than aLOAD. No differences in MTL tau-PET or transactive response DNA binding protein 43-proxy positivity were found. Conclusions: We found evidence for MTL atrophy in amnestic EOAD and overall similar levels to aLOAD of MTL tau pathology and co-pathologies.
- Open Access
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease
Background: The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfield volumes and drivers of atrophy in amnestic EOAD is lacking. Methods: BioFINDER-2 participants with memory impairment, abnormal amyloid-β status and tau-PET were included. Forty-one EOAD individuals aged ≥65 years and, as comparison, late-onset AD (LOAD, ≤70 years, n=154) and Aβ-negative cognitively unimpaired controls were included. MTL subregions and biomarkers of (co-)pathologies were measured. Results: AD groups showed smaller MTL subregions compared to controls. Atrophy patterns were similar across AD groups, although LOAD showed thinner entorhinal cortices compared to EOAD. EOAD showed lower WMH compared to LOAD. No differences in MTL tau-PET or transactive response DNA binding protein 43-proxy positivity was found. Conclusions: We found in vivo evidence for MTL atrophy in amnestic EOAD and overall similar levels to LOAD of MTL tau pathology and co-pathologies.
Open AccessMedial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease
Background: The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfield volumes and drivers of atrophy in amnestic EOAD is lacking. Methods: BioFINDER-2 participants with memory impairment, abnormal amyloid-β status and tau-PET were included. Forty-one EOAD individuals aged ≥65 years and, as comparison, late-onset AD (LOAD, ≤70 years, n=154) and Aβ-negative cognitively unimpaired controls were included. MTL subregions and biomarkers of (co-)pathologies were measured. Results: AD groups showed smaller MTL subregions compared to controls. Atrophy patterns were similar across AD groups, although LOAD showed thinner entorhinal cortices compared to EOAD. EOAD showed lower WMH compared to LOAD. No differences in MTL tau-PET or transactive response DNA binding protein 43-proxy positivity was found. Conclusions: We found in vivo evidence for MTL atrophy in amnestic EOAD and overall similar levels to LOAD of MTL tau pathology and co-pathologies.
- Open Access
- 24 April 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2400-2413
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.
- 24 April 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2400-2413
Open AccessA generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.
- Open Access
- 28 February 2024
- Published by Wiley in Hippocampus
- Vol. 34 (5) , 241-260
Comparison of histological delineations of medial temporal lobe cortices by four independent neuroanatomy laboratories
The medial temporal lobe (MTL) cortex, located adjacent to the hippocampus, is crucial for memory and prone to the accumulation of certain neuropathologies such as Alzheimer's disease neurofibrillary tau tangles. The MTL cortex is composed of several subregions which differ in their functional and cytoarchitectonic features. As neuroanatomical schools rely on different cytoarchitectonic definitions of these subregions, it is unclear to what extent their delineations of MTL cortex subregions overlap. Here, we provide an overview of cytoarchitectonic definitions of the entorhinal and parahippocampal cortices as well as Brodmann areas (BA) 35 and 36, as provided by four neuroanatomists from different laboratories, aiming to identify the rationale for overlapping and diverging delineations. Nissl‐stained series were acquired from the temporal lobes of three human specimens (two right and one left hemisphere). Slices (50 μm thick) were prepared perpendicular to the long axis of the hippocampus spanning the entire longitudinal extent of the MTL cortex. Four neuroanatomists annotated MTL cortex subregions on digitized slices spaced 5 mm apart (pixel size 0.4 μm at 20× magnification). Parcellations, terminology, and border placement were compared among neuroanatomists. Cytoarchitectonic features of each subregion are described in detail. Qualitative analysis of the annotations showed higher agreement in the definitions of the entorhinal cortex and BA35, while the definitions of BA36 and the parahippocampal cortex exhibited less overlap among neuroanatomists. The degree of overlap of cytoarchitectonic definitions was partially reflected in the neuroanatomists' agreement on the respective delineations. Lower agreement in annotations was observed in transitional zones between structures where seminal cytoarchitectonic features are expressed less saliently. The results highlight that definitions and parcellations of the MTL cortex differ among neuroanatomical schools and thereby increase understanding of why these differences may arise. This work sets a crucial foundation to further advance anatomically‐informed neuroimaging research on the human MTL cortex.
- 28 February 2024
- Published by Wiley in Hippocampus
- Vol. 34 (5) , 241-260
Open AccessComparison of histological delineations of medial temporal lobe cortices by four independent neuroanatomy laboratories
The medial temporal lobe (MTL) cortex, located adjacent to the hippocampus, is crucial for memory and prone to the accumulation of certain neuropathologies such as Alzheimer's disease neurofibrillary tau tangles. The MTL cortex is composed of several subregions which differ in their functional and cytoarchitectonic features. As neuroanatomical schools rely on different cytoarchitectonic definitions of these subregions, it is unclear to what extent their delineations of MTL cortex subregions overlap. Here, we provide an overview of cytoarchitectonic definitions of the entorhinal and parahippocampal cortices as well as Brodmann areas (BA) 35 and 36, as provided by four neuroanatomists from different laboratories, aiming to identify the rationale for overlapping and diverging delineations. Nissl‐stained series were acquired from the temporal lobes of three human specimens (two right and one left hemisphere). Slices (50 μm thick) were prepared perpendicular to the long axis of the hippocampus spanning the entire longitudinal extent of the MTL cortex. Four neuroanatomists annotated MTL cortex subregions on digitized slices spaced 5 mm apart (pixel size 0.4 μm at 20× magnification). Parcellations, terminology, and border placement were compared among neuroanatomists. Cytoarchitectonic features of each subregion are described in detail. Qualitative analysis of the annotations showed higher agreement in the definitions of the entorhinal cortex and BA35, while the definitions of BA36 and the parahippocampal cortex exhibited less overlap among neuroanatomists. The degree of overlap of cytoarchitectonic definitions was partially reflected in the neuroanatomists' agreement on the respective delineations. Lower agreement in annotations was observed in transitional zones between structures where seminal cytoarchitectonic features are expressed less saliently. The results highlight that definitions and parcellations of the MTL cortex differ among neuroanatomical schools and thereby increase understanding of why these differences may arise. This work sets a crucial foundation to further advance anatomically‐informed neuroimaging research on the human MTL cortex.